A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Doses of Inhaled R940343 in Patients With Mild to Moderate Allergic Asthma
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2016
At a glance
- Drugs R 343 (Primary)
- Indications Allergic asthma
- Focus Therapeutic Use
- Acronyms SITAR
- 26 Aug 2013 Primary endpoint 'Forced-expiratory-volume-in-1-second' has not been met according to a Rigel Pharmaceuticals media release.
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.